COST-EFFECTIVENESS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN FILIPINO ADULTS AGED $50 YEARS

被引：0
作者：
Santiaguel, J. [1 ]
Nua, W. [2 ]
Atwood, M. [3 ]
Huang, L. [4 ]
Hariharan, D. [3 ]
Guerrero, J. [2 ]
Zotomayor, R. C. [5 ]
Averin, A.
机构：
[1] IUP PGH Med Ctr, Manila, Philippines
[2] Pfizer Inc, Makati, Philippines
[3] Policy Anal Inc PAI, Boston, MA USA
[4] Pfizer Inc, Collegeville, PA USA
[5] UERMMMC Inc SLMC, Quezon City, Philippines
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE592
引用
收藏
页码：S167 / S167
页数：1
相关论文
共 50 条
[21]   Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia [J].
Sundaram, Neisha ;
Chen, Cynthia ;
Yoong, Joanne ;
Luvsan, Munkh-Erdene ;
Fox, Kimberley ;
Sarankhuu, Amarzaya ;
La Vincente, Sophie ;
Jit, Mark .
VACCINE, 2017, 35 (07) :1055-1063
[22]   COST-EFFECTIVENESS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN KAZAKHSTAN [J].
Bektur, C. ;
Nurgozhin, T. .
VALUE IN HEALTH, 2015, 18 (03) :A106-A106
[23]   Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions [J].
Cho, Bo-Hyun ;
Stoecker, Charles ;
Link-Gelles, Ruth ;
Moore, Matthew R. .
VACCINE, 2013, 31 (50) :6011-6021
[24]   Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians [J].
Dirmesropian, S. ;
Wood, J. G. ;
MacIntyre, C. R. ;
Beutels, P. ;
McIntyre, P. ;
Menzies, R. ;
Reyes, J. F. ;
Chen, C. ;
Newall, A. T. .
VACCINE, 2017, 35 (34) :4307-4314
[25]   COST-EFFECTIVENESS OF A 13-VALENT CONJUGATE PNEUMOCOCCAL VACCINATION PROGRAM IN COPD PATIENTS AGED ≥50 YEARS IN SPAIN: PRELIMINARY RESULTS [J].
Menendez, R. ;
Rodriguez-GonzalezMoro, J. M. ;
Gros, B. ;
Echave, M. ;
Oyagueez, I ;
Lwoff, N. ;
Egea-Garcia, M. ;
Guijarro, P. .
VALUE IN HEALTH, 2013, 16 (07) :A353-A353
[26]   Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years [J].
Weycker, Derek ;
Sato, Reiko ;
Strutton, David ;
Edelsberg, John ;
Atwood, Mark ;
Jackson, Lisa A. .
VACCINE, 2012, 30 (36) :5437-5444
[27]   COST-EFFECTIVENESS OF SWITCHING FROM THE 10-VALENT TO THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN SWEDEN [J].
Wasserman, M. ;
Dorange, A. C. ;
Palmborg, A. ;
McDade, C. ;
Wilson, M. ;
Horn, E. .
VALUE IN HEALTH, 2022, 25 (01) :S110-S110
[28]   COST-EFFECTIVENESS OF SWITCHING STRATEGIES FROM A 7-VALENT TO A 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE [J].
Claes, C. ;
Mittendorf, T. ;
Kuchenbecker, U. ;
Rose, M. ;
Reinert, R. R. .
VALUE IN HEALTH, 2009, 12 (07) :A425-A425
[29]   Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults [J].
Mark Atwood ;
Linda Beausoleil ;
Marie-Claude Breton ;
Craig Laferriere ;
Reiko Sato ;
Derek Weycker .
Canadian Journal of Public Health, 2018, 109 :756-768
[30]   Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults [J].
Atwood, Mark ;
Beausoleil, Linda ;
Breton, Marie-Claude ;
Laferriere, Craig ;
Sato, Reiko ;
Weycker, Derek .
CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2018, 109 (5-6) :756-768
12345